Can shedding pounds calm psoriatic arthritis? new study investigates

NCT ID NCT07443956

Recruiting now Knowledge-focused Sponsor: NHS Greater Glasgow and Clyde Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how weight loss (using tirzepatide) and a biologic drug (ixekizumab) affect the body in people with psoriatic arthritis who are overweight or obese. About 45 adults will receive one or both treatments. Researchers will take samples of skin, joint tissue, and fat at the start and after 12 weeks to see what changes occur. The goal is to understand how these treatments work at the tissue level, not to test if they cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT PSORIATIC ARTHRITIS (PSA)

Contacts and locations

Locations

NHS Greater Glasgow and Clyde
RECRUITING

Glasgow, Scotland, G12 0XH, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
NOT_YET_RECRUITING

Newcastle upon Tyne, England, NE7 7DN, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
NOT_YET_RECRUITING

Birmingham, England, B12 2GW, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust
NOT_YET_RECRUITING

Coventry, England, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.